Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006.
The optimal age for measles vaccination is an important health issue, since maternal antibodies may neutralize the vaccine antigen before a specific immune response develops, while delaying vaccination may increase the risk of complicated diseases in infants. However, measles vaccination impacts the duration of protection afforded by transplacental transfer of maternal antibodies: vaccination-induced maternal antibodies disappear faster than disease-induced antibodies. In order to maintain protection against measles in infants, it is important to monitor the dynamics of this phenomenon in vaccinated populations. To assess the current situation in France, a multicenter, prospective seroepidemiological study was conducted in seven French hospitals between October 2005 and January 2007. Maternal measles antibody concentrations from 348 infants 0 to 15 months old were measured using the plaque reduction neutralization assay. Geometric mean concentrations and the percentage of infants with maternal measles antibody concentrations above the protection threshold (>or=120 mIU/ml) were assessed according to age. Results show that after more than 20 years of routine measles vaccination in France, maternal measles-neutralizing antibodies decrease dramatically in French infants by 6 months of age, from 1,740 mIU/ml for infants 0 to 1 month old to 223 mIU/ml for infants 5 to 6 months old, and that 90% of infants are not protected against measles after 6 months of age. Infant protection against measles could be optimized both by increasing herd immunity through an increased vaccine coverage and by lowering the age of routine vaccination from 12 to 9 months.
Gagneur
Arnaud
A
CHU Brest, Brest, France. arnaud.gagneur@usherbrooke.ca
Pinquier
Didier
D
Aubert
Marie
M
Balu
Laurent
L
Brissaud
Olivier
O
De Pontual
Loïc
L
Gras Le Guen
Christèle
C
Hau-Rainsard
Isabelle
I
Mory
Olivier
O
Picherot
Georges
G
Stephan
Jean-Louis
JL
Cohen
Bernard
B
Caulin
Evelyne
E
Soubeyrand
Benoît
B
Reinert
Philippe
P
D000914:Antibodies, Viral / Q000097:blood*; D005602:France / Q000453:epidemiology; D006801:Humans; D007112:Immunity, Maternally-Acquired / Q000276:immunology*; D007116:Immunization, Passive; D007223:Infant; D007700:Kinetics; D008457:Measles / Q000097:blood / Q000276:immunology*; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D009500:Neutralization Tests; D011446:Prospective Studies
D000914:Antibodies, Viral; D008458:Measles Vaccine